Eplerenone: The first selective aldosterone receptor antagonist for the treatment of hypertension

Formulary

Volumn 37, Issue 10, 2002, Pages 514-524

  Coleman, Craig I ^a   Reddy, Prabashni ^a   Song, Jessica C ^a   White, C Michael ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANDROGEN RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LOSARTAN; PROGESTERONE RECEPTOR; SPIRONOLACTONE;

AREA UNDER THE CURVE; BINDING AFFINITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; FOOD DRUG INTERACTION; GYNECOMASTIA; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; MORTALITY; QUALITY OF LIFE; REVIEW;

EID: 0036798075     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-43.
2. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.
3. Dipiro JT, Talbert RL, Yee GC et al, eds. Pharmacotherapy: A Pathophysiological Approach, 4th ed. Stamford, CT: Appleton and Lange; 1999.
4. Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care 2002;25:134-47.
5. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Card Fail 1999;5:357-82.
6. McKelvie RS, Yusaf S, Pericak D, et al. Comparison of candasartan, enalapril, and their combination in congestive heart failure. Randomized evaluation of the strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999;100:1056-64.
7. Weinberger MH. Salt sensitivity and blood pressure in humans. Hypertension 1996;27:481-90.
8. Flack JM, Mamaty M. Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes. J Hypertens Suppl 1999;17:S19-24.
9. Aldactone [package insert]. Chicago, IL: Pharmacia;. 2001.
10. Jeunemaitre X, Chantellier G, Kreft-Jais, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-5.
11. Funder JW. Eplerenone, a new mineralocorticoid antagonist: In vitro and in vivo studies. Curr Opin Endocrinol Diabetes 2000;7:138-42.
12. Delyani JA, Rocha R, Cook CS, et al. Eplerenone: A selective aldosterone receptor antagonist (SARA). Cardio Drug Rev 2001;3:185-200.
13. de Gaspo M, Joss U, Ramioue HP, et al. Three new-epoxyspironolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-6.
14. Roniker B. Eplerenone, a selective antagonist of the aldosterone receptor [abstract]. Hypertension 1997;30:995; Abstract 67.
15. Tolbert D, Karim A, Cook C, et al. SC-66110 (Eplerenone): A selective antialdosterone antagonist. Disposition kinetics in man and identification of its major CYP450 isoenzyme in its biotransformation [abstract]. AAPS PharmSci Suppl 1998;1 Abstract 1155.
16. Tolbert DS, Karim A, Nasafi J, et al. Effect of double strength grapefruit juice on the pharmacokinetics of eplerenone [abstract]. AAPS PharmSci Suppl 2000;2 Abstract 1813.
17. Tolbert DS, Karim A, Masafi J, et al. Eplerenone biotransformation: Ketoconazole but not fluconazole substantially increases eplerenone exposure in man [abstract]. AAPS PharmSci Suppl 2000;2 Abstract 1814.
18. Cook CS, Zhang L, Fischer J. Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog. Pharm Res 2000;17:1426-31.
19. Burgess E, Lacourciere Y, Puopolo A, et al. The selective aldosterone blocker eplerenone is safe and efficacious for the long-term treatment of mild-to-moderate hypertension [abstract]. Am J Hypertens 2002;15(suppl):57A-58A.
20. White WB, Oigman W, Mion D, et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinic BP in 400 patients with systolic hypertension: Results from a pivotal multinational trial [abstract]. Am J Hypertens 2002;15(suppl):118A.
21. Epstein M, Menard J, Alexander JC, et al. Eplerenone, a novel and selective aldosterone receptor antagonist efficacy in patients with mild to moderate hypertension [absrxact]. Circulation 1998;98z(suppl):198-99.
22. Weinberger M. MacDonald T, Conlin PR, et al. Comparison of eplerenone and losartan in patients with low-renin hypertension. Am J Hypertens 2002;15(suppl):24A.
23. Pratt JH, Flack JM, Wright JT, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients [abstract]. Am J Hypertens 2002;15(suppl):213A.
24. Burgess E, Niegowska J, Tan W, et al. Antihypertensive effects of eplerenone and enalapril in patients with essential hypertension [abstract]. Am J Hypertens 2002;15(suppl):15:23A.
25. White WB, Lewin AJ, Nestel R, et al. Comparison of selective aldosterone blockade versus calcium channel antagonism on blood pressure, vascular compliance, and microalbumineria in systolic hypertension in older people [abstract]. Am J Hypertens 2002;15(suppl):23A.
26. Krum H, Nolly H, Roniker B, et al. Coadministration of eplerenone with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker in patients with mild to moderate hypertension [abstract]. Eur Heart J 2001;22:612.
27. Pitt B, Reichek N, Metscher B, et al. Efficacy and safety of eplerenone, enalapril and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy [abstract]. Am J Hypertens 2002;15(suppl):23A-24A.
28. Epstein M, Buckalew V, Altamirano J, et al. Eplerenone reduces proteinuria in type II diabetes mellitus: Implications for aldosterone involvement in the pathogenesis of renal dysfunction [abstract]. J Am Coll Cardiol 2002;39(suppl A):249A;Abstract 843FO-4.
29. Pitt B William G, Remme W, et al. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Cardiovasc Drugs Ther 2001;15:79-87.
30. Spertus JA, Tooley J, Jones P, et al. Expanding the outcomes in clinical trials of heart failure: The quality of life and economic components of EPHESUS (EPLerenone's neuroHormonal Efficacy and Survival Study). Am Heart J 2002;143:636-42.
31. RALES investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure The Randomized Aldactone Evaluation Study (RALES). Am J Cardiol 1996;78:902-7.
32. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
33. Multiple studies show eplerenone to be a potent antihypertensive agent. Formulary 2002;37:338-41.
34. Pitt B, Roniker B. Eplerenone, a novel selective aldosterone receptor antagonist (SARA): Dose finding study in patients with heart failure [abstract]. J Am Coll Cardiol 1999;33(suppl 2): 188A-189A.
35. Martin J and Krum H. Eplerenone. Curr Opin Invest Drugs 2001;2:521-24.